Inhibikase Therapeutics (IKT) Cash & Current Investments (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Cash & Current Investments data on file, last reported at $170.4 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $170.4 million, up 82.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $170.4 million (up 82.84% YoY), and the FY2025 annual result was $178.8 million, up 83.27% from the prior year.
• Cash & Current Investments fell to $170.4 million in Q1 2026 per IKT's latest filing, from $178.8 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $178.8 million in Q4 2025 and troughed at $3.2 million in Q3 2024.
• A 5-year average of $54.2 million and a median of $26.5 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments slumped 80.73% in 2024, then jumped 2283.81% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $23.1 million in 2022, then slumped by 42.51% to $13.3 million in 2023, then soared by 636.06% to $97.5 million in 2024, then jumped by 83.27% to $178.8 million in 2025, then retreated by 4.7% to $170.4 million in 2026.
• Business Quant data shows IKT's Cash & Current Investments at $170.4 million in Q1 2026, $178.8 million in Q4 2025, and $77.3 million in Q3 2025.